Application
Quality Control Testing
Evaluated by Western Blotting in rat heart tissue lysate.
Western Blotting Analysis: A 1:1,000 dilution of this antibody detected TRIM63 in rat heart tissue lysate.
Tested Applications
Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected TRIM63 in lysates from human skeletal muscle tissue and mouse heart tissue.
Affinity Binding Assay: A representative lot of this antibody bound TRIM63 peptide with at least one thousand-fold (1,000X) higher affinity than with non-specific control peptide.
Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected TRIM63 in HeLa cells.
Immunohistochemistry (Paraffin) Analysis: A 1:1,000 dilution from a representative lot detected TRIM63 in human skeletal muscle tissue sections.
Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.
Biochem/physiol Actions
Clone 3M21 is a ZooMAb® recombinant rabbit monoclonal antibody that specifically detects TRIM63. It targets an epitope within 19 amino acids from the C-terminal half. The Antibody is predicted to react with all isoforms of TRIM63.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
General description
E3 ubiquitin-protein ligase TRIM63 (UniProt: Q969Q1 also known as Iris RING finger protein, Muscle-specific RING finger protein 1, MuRF-1, MuRF1, RING finger protein 28, RING-type E3 ubiquitin transferase TRIM63, Striated muscle RING zinc finger protein, Tripartite motif-containing protein 63, EC:2.3.2.27) is encoded by the TRIM63 (also known as IRF, MURF1, RNF28, SMRZ) gene (Gene ID: 84676) in human. This gene encodes a member of the RING zinc finger protein family found in striated muscle and iris. The product of this gene is localized to the Z-line and M-line lattices of myofibrils, where titin s N-terminal and C-terminal regions respectively bind to the sarcomere. TRIM63 plays an integral role in the regulation of muscle protein degradation and overall muscle mass homeostasis. Structurally, TRIM63 contains a RING-type zinc finger, B box-type zinc finger and coiled-coil motifs, enabling it to function as a multi-domain protein that interacts with various substrates, particularly myofibrillar proteins such as myosin heavy chain and alpha-actin. This protein is predominantly expressed in skeletal and cardiac muscle tissues, where it localizes to the cytoplasm and sarcomeres, facilitating the ubiquitination of muscle proteins for degradation via the ubiquitin-proteasome system. Two isoforms of TRIM63 have been described that are produced by alternative splicing. Dysregulation of TRIM63 is implicated in several pathologies, including hypertrophic cardiomyopathy (HCM) and chronic kidney disease (CKD), where its overexpression contributes to muscle wasting and podocyte injury, respectively. Studies have shown that TRIM63 is upregulated in conditions such as ventilator-induced diaphragmatic dysfunction (VIDD) and diabetic nephropathy, highlighting its potential as a therapeutic target for muscle atrophy and related disorders. Recent research identifies TRIM63 as a vital genetic marker for hypertrophic cardiomyopathy. This ZooMAb® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (ref.: Chen, Q., et al. (2023). Free Radic Biol Med. 209; 40-54; Liu, J., et al. (2025). Mitochondrion. 83; 102025; Ruhrman-Shahar, N., et al. (2025). Circ Genom Precis Med. 18 (1); e004864).
ZooMAb® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb® antibodies are reliably available and ready to ship when you need them.
Immunogen
KLH-conjugated linear peptide corresponding to 19 amino acids from the C-terminal half of human TRIM63.
Physical form
Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.
Preparation Note
300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
Legal Information
ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany